InsidersTradesSigma
Total declarations
Company
▲ Purchases (11 ops.)
▼ Sales (0 ops.)
Insider track record
CEODisclosed buys
11
Disclosed sells
0
T+90 hit rate
0%
T+90 mean return
-23.2%
Across 7 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the full record of transactions filed by Huntsman Ronald Kirk, Chief Executive Officer. Insider active across 1 company, notably Vivos Therapeutics, Inc.. Aggregated, 11 reports have been recorded. Breakdown: 11 buys · 0 sell. Total volume traded: €133k. History available since 25 May 2021. The latest transaction was filed on 20 June 2023 (Acquisition). Regulator: SEC (Form 4). The full history is accessible without signup.
Declarations11 total
14,000 shares@ US$0.535.1% of flowCommon StockSEC:0001493152-23-021910:0
Ideal exit: 16 Mar 2024 (T+270)
21 shares@ US$0.500.0% of flowCommon StockSEC:0001493152-23-021751:0
Ideal exit: 11 Mar 2024 (T+270)
10,000 shares@ US$0.493.4% of flowCommon StockSEC:0001493152-23-021525:0
Ideal exit: 10 Mar 2024 (T+270)
20,000 shares@ US$0.507.1% of flowCommon StockSEC:0001493152-22-036727:0
Ideal exit: 19 Sept 2023 (T+270)
8,000 shares@ US$2.030.17% mcap13.4% of flowCommon StockSEC:0001493152-22-015773:0
Ideal exit: 25 Feb 2023 (T+270)
5,000 shares@ US$4.3113.8% of flowCommon StockSEC:0001493152-21-023354
Ideal exit: 18 Jun 2022 (T+270)
5,000 shares@ US$4.310.21% mcap16.3% of flowCommon StockSEC:0001493152-21-023354:0
Ideal exit: 18 Jun 2022 (T+270)
5,000 shares@ US$3.009.6% of flowCommon StockSEC:0001493152-21-020536
Ideal exit: 14 May 2022 (T+270)
5,000 shares@ US$3.000.15% mcap11.4% of flowCommon StockSEC:0001493152-21-020536:0
Ideal exit: 14 May 2022 (T+270)
4,000 shares@ US$5.380.20% mcap15.6% of flowCommon StockSEC:0001493152-21-012901:0
Ideal exit: 19 Feb 2022 (T+270)
4,000 shares@ US$5.3815.6% of flowCommon StockSEC:0001493152-21-012901
Ideal exit: 19 Feb 2022 (T+270)
11 of 11 declarations
About Huntsman Ronald Kirk
Ronald Kirk Huntsman is the Chief Executive Officer of Vivos Therapeutics, Inc. In this role, he is responsible for the strategic and operational leadership of the company. Ronald Huntsman plays a key role in developing innovative therapeutic solutions and optimizing the company's performance. His expertise in management and healthcare is essential for the success of Vivos Therapeutics.
